Featured Research

from universities, journals, and other organizations

Psoriasis patients face higher than average death risk after a heart attack

Date:
September 12, 2011
Source:
Wiley-Blackwell
Summary:
Heart attack patients with psoriasis are 26 percent more likely to die from cardiovascular disease, or suffer from recurrent heart attacks or strokes, and are 18 percent more likely to die from all causes than those without the inflammatory skin disease. Researchers studied nearly 50,000 patients who had experienced their first heart attack between 2002 and 2006, following the 462 patients with psoriasis for an average of 19.5 months and the 48,935 controls for an average of 22 months.

Heart attack patients with psoriasis are 26 per cent more likely to die from cardiovascular disease, or suffer from recurrent heart attacks or strokes, and are 18 per cent more likely to die from all causes than those without the inflammatory skin disease. That's the key finding of a Danish study published in the September issue of the Journal of Internal Medicine.

Researchers studied nearly 50,000 patients who had experienced their first heart attack between 2002 and 2006, following the 462 patients with psoriasis for an average of 19.5 months and the 48,935 controls for an average of 22 months.

They found that the patients with psoriasis had higher all-cause and specific death rates and say this indicates the need for a more aggressive approach to secondary prevention of cardiovascular disease in this group of patients.

"Psoriasis is a common skin condition that is estimated to affect 125 million people worldwide" explains lead author and cardiologist Dr Ole Ahlehoff, from Copenhagen University Hospital Gentofte.

"It is a chronic inflammatory condition where the skin cells we naturally shed all the time are replaced much quicker than normal, leading to a build up of psoriatic plaque. Heart attacks are also caused by a build-up of plaque, in the arteries leading to the heart. Our study explored the links between the two conditions, which appear to have similar inflammatory mechanisms."

Key finding of the study included:

  • The incidence rates per 1000 patient years for all-cause deaths were 16 per cent higher for those with psoriasis (138.3 versus 119.4) and the adjusted hazard ratio was 1.18 (18 per cent higher).
  • The incidence rates per 1000 patient years for deaths for a composite of cardiovascular death, recurrent heart attacks or stroke were 24 per cent higher for those with psoriasis (185.6 versus 149.7) and the adjusted hazard ratio was 1.26 (26 per cent higher).
  • Baseline measurements showed that patients with psoriasis had a higher rate of hospitalisation for stable and / or unstable angina (severe chest pain). They also showed that a higher percentage of patients with psoriasis were treated with statins and ACE inhibitors / angiotensin 2 receptor blockers.
  • Patients with psoriasis who survived their first heart attack were more likely to receive statin therapy than those without psoriasis. However the presence of other health issues, and the differences in clinical management, did not explain the worsened prognosis in patients with psoriasis.

"To our knowledge, this is the first study to assess the prognosis in patients with psoriasis following a heart attack" says Dr Ahlehoff. "Our findings show that people with psoriasis demonstrated a significantly increased risk of recurring adverse cardiovascular events and a trend for increased all-cause deaths after a heart attack.

"Furthermore, the poor prognosis faced by psoriasis patients who have had a heart attack suggests the need for a more aggressive approach to secondary prevention of cardiovascular disease in this group of patients."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. O. Ahlehoff, G. H. Gislason, J. Lindhardsen, J. B. Olesen, M. Charlot, L. Skov, C. Torp-Pedersen, P. R. Hansen. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. Journal of Internal Medicine, 2011; 270 (3): 237 DOI: 10.1111/j.1365-2796.2011.02368.x

Cite This Page:

Wiley-Blackwell. "Psoriasis patients face higher than average death risk after a heart attack." ScienceDaily. ScienceDaily, 12 September 2011. <www.sciencedaily.com/releases/2011/09/110912102116.htm>.
Wiley-Blackwell. (2011, September 12). Psoriasis patients face higher than average death risk after a heart attack. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/09/110912102116.htm
Wiley-Blackwell. "Psoriasis patients face higher than average death risk after a heart attack." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912102116.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins